Effect of pembrolizumab on biomarkers related to intratumoral immunity, proliferation and apoptosis in early breast cancer KU Leuven
Up to thirty percent of patients with early breast cancer (BC) will eventually develop metastases. This results in an ongoing search for treatments to improve the long-term survival of these patients. Immune checkpoint inhibitors (ICI) are one promising type of therapeutic targets and have shown good results in malignancies as melanoma and non-small cell lung cancer. In BC, and especially in triple negative BC (TNBC), a clinical benefit for ...